Ropes & Gray advised South Korean biotechnology company SK Biopharmaceuticals in a in a global licensing agreement with radiotherapy company Full-Life Technologies for exclusive worldwide clinical research, development, manufacturing and commercialization rights to Full-Life’s FL-091 radiopharmaceutical compound designed to deliver targeted radiation therapy to a certain receptor protein which is selectively overexpressed in various types of solid tumors, including colorectal cancer, prostate cancer, and pancreatic cancer.
The licensing deal is worth $571.5 million and includes an upfront payment, and development and commercial milestones, separate from royalties.
Under the agreement, SK Biopharmaceuticals will in-license the NTSR1-targeting Radionuclide Drug Conjugate (RDC) program FL-091 and its back-up compounds with the goal of developing and commercializing it as an innovative anti-cancer drug. SK Biopharmaceuticals also has a right of first negotiation to license other pre-selected RDC programs of Full-Life.
The Ropes & Gray team included IP transactions partner Geoffrey Lin, IP transactions counsel Georgina Jones Suzuki and IP transactions associate Derek Mubiru
Where the legal industry reads first.
Enjoyed this article? Get the biggest legal industry updates, deals, appointments, insights and expert interviews in your inbox, free.
No spam. Unsubscribe anytime.
